TAVR for Aortic Valve Disease

Launched by NANJING FIRST HOSPITAL, NANJING MEDICAL UNIVERSITY · Jun 26, 2022

Keywords

ClinConnect Summary

This clinical trial is focused on studying a procedure called Transcatheter Aortic Valve Replacement (TAVR), which is a treatment for severe aortic stenosis, a condition where the heart's aortic valve becomes narrowed. TAVR is a less invasive option compared to traditional surgery and has shown promising results in previous studies. However, there are still many questions about its use, especially in younger patients, valve durability, and other specific situations. To answer these questions, researchers are collecting real-world data from multiple medical centers.

To participate in this trial, you need to have a clinical diagnosis of severe aortic stenosis or aortic regurgitation and be planning to undergo the TAVR procedure. The study is currently recruiting participants aged 65 to 74, and anyone can join regardless of gender, as long as they agree to follow up with the doctors after the procedure. If you take part, you can expect regular check-ins to monitor your health and the performance of the new valve. This trial aims to provide valuable information that could help improve treatment options for patients with aortic valve disease in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Clinical diagnosis of severe aortic stenosis or aortic regurgitation
• • 2. Patients undergo transcatheter aortic valve replacement
• Exclusion Criteria:
• • patients refuse the clinical follow-up